Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial
NCT ID: NCT01269788
Last Updated: 2012-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
144 participants
INTERVENTIONAL
2010-08-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Treatment of NERD can be a challenge for clinicians. According to the many studies , the pooled rate for symptomatic response after a period of proton pomp inhibitor(PPIs)therapy as the most frequently used drug, in NERD patients is lower than for erosive esophagitis patients. It is also shown that acid exposure is much lower in NERD patients than those with erosive esophagitis and NERD patients are less likely to exhibit a strong association between heartburn symptoms and acid reflux events than patients with erosive oesophagitis.
Furthermore, beside the high economic burden, there are concerns about the adverse effects of long time administration of PPIs.
Several hypothesis has been proposed to describe low response rate of NERD patients to PPIs. One of the most acceptable theories is that patients with anxiety or depression and psychological problems are at an increased risk of developing reflux symptoms. On the other hand, pain modulators such as sertraline, a selective serotonin reuptake inhibitor(SSRI), and other antidepressants have been shown to improve symptoms in patients with functional gastrointestinal disorders like non cardiac chest pain.
According to the above-mentioned tips, the investigators hypothesize that antidepressants like fluoxetine, as an SSRI, may have beneficial effects in improving symptoms of NERD patients.
The purpose of this study is to compare the effect of omeprazole with fluoxetine and placebo for treatment of NERD patients and its subgroups who all experience reflux symptoms and have normal endoscopic findings.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
NCT00259077
A Study to Investigate the Pharmacodynamic Effect After Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population
NCT00259051
Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
NCT01119768
Omepral® Tablets Special Clinical Experience Investigation in Patients With Erosive Esophagitis
NCT00859287
Efficacy of Traditional Chinese Medicine Combined With Omeprazole in Patients With Non-erosive Reflux Disease
NCT02892357
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
pH positive-omeprazole
Omeprazole
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
pH positive-placebo
placebo
oral , daily 30 mins before breakfast, for 6 weeks
pH positive-fluoxetine
Fluoxetine
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
pH negative-omeprazole
Omeprazole
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
pH negative-fluoxetine
Fluoxetine
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
pH negative-placebo
placebo
oral , daily 30 mins before breakfast, for 6 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fluoxetine
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Omeprazole
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
placebo
oral , daily 30 mins before breakfast, for 6 weeks
Omeprazole
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
Fluoxetine
20 mg , oral , daily 30 mins before breakfast, for 6 weeks
placebo
oral , daily 30 mins before breakfast, for 6 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* experiencing heartburn during last 6 months before inclusion
* experiencing heartburn during at least 4 of 7 days before inclusion
* presence of normal mucosa in upper gastrointestinal(GI) endoscopy which has been documented during 7 days before inclusion provided that the patient has not administered any PPI during last 30 days before inclusion
Exclusion Criteria
* presence of barret's esophagus or erosive esophagitis in upper GI endoscopy
* presence of active peptic ulcer disease or any disease which affects the absorption of drugs such as inflammatory bowel disease
* past history of esophageal or gastric surgery
* esophageal stricture which needs dilation
* administration of proton pomp inhibitors during 30 days before inclusion to the study
* administration of H2 blockers, anticholinergics, sucralfate and pro-kinetics during the assessments for eligibility and also during the study
* long time administration of non-steroidal anti-inflammatory drugs (NSAIDs)
* administration of neuroleptic or antidepressant drugs during 30 days before inclusion to the study
* known allergy to PPIs or SSRIs
* presence of significant systemic disease such as scleroderma , diabet mellitus , peripheral and autonomic neuropathies and ...
* pregnancy for females
* presence of known psychiatric disorder such as depression , panic disorder or drug addiction according to the DSM-IV criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tehran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seyed Amir Mirbagheri, MD
Role: STUDY_CHAIR
Department of Internal Medicine, Faculty of medicine, Tehran university of medical sciences
Mohammad Reza Ostovaneh, MD,MPH
Role: PRINCIPAL_INVESTIGATOR
Tehran University of Medical Sciences
Arash Etemadi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Tehran University of Medical Sciences
Yasin Farrokhi Khajeh Pasha, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Tehran University of Medical Sciences
Behtash Saeidi, MD
Role: PRINCIPAL_INVESTIGATOR
Tehran University of Medical Sciences
Kaveh Hajifathalian, MD
Role: PRINCIPAL_INVESTIGATOR
Tehran University of Medical Sciences
Akbar Fotouhi, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Tehran University of Medical Sciences
Seyed Mahmoud Eshagh hosseini, MD
Role: PRINCIPAL_INVESTIGATOR
Tehran University of Medical Sciences
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gasterointestinal endoscopy ward, Amir Alam hospital, Tehran university of medical sciences
Tehran, Tehran Province, Iran
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009 Mar;104 Suppl 2:S27-32. doi: 10.1038/ajg.2009.49.
Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R. Non-erosive reflux disease (NERD)--acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003 Feb 15;17(4):537-45. doi: 10.1046/j.1365-2036.2003.01423.x.
Raghunath AS, O'Morain C, McLoughlin RC. Review article: the long-term use of proton-pump inhibitors. Aliment Pharmacol Ther. 2005 Aug;22 Suppl 1:55-63. doi: 10.1111/j.1365-2036.2005.02611.x.
Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol. 2004 Aug;2(8):656-64. doi: 10.1016/s1542-3565(04)00288-5.
Bradley LA, Richter JE, Pulliam TJ, Haile JM, Scarinci IC, Schan CA, Dalton CB, Salley AN. The relationship between stress and symptoms of gastroesophageal reflux: the influence of psychological factors. Am J Gastroenterol. 1993 Jan;88(1):11-9.
DeVault KR. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther. 2006 Mar;23 Suppl 1:33-9. doi: 10.1111/j.1365-2036.2006.02798.x.
Venes DJ. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994 Sep 29;331(13):882; author reply 882-3. No abstract available.
Handa M, Mine K, Yamamoto H, Hayashi H, Tsuchida O, Kanazawa F, Kubo C. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol. 1999 Apr;28(3):228-32. doi: 10.1097/00004836-199904000-00008.
Varia I, Logue E, O'connor C, Newby K, Wagner HR, Davenport C, Rathey K, Krishnan KR. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000 Sep;140(3):367-72. doi: 10.1067/mhj.2000.108514.
Broekaert D, Fischler B, Sifrim D, Janssens J, Tack J. Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2006 Feb 1;23(3):365-70. doi: 10.1111/j.1365-2036.2006.02772.x.
Rentz AM, Kahrilas P, Stanghellini V, Tack J, Talley NJ, de la Loge C, Trudeau E, Dubois D, Revicki DA. Development and psychometric evaluation of the patient assessment of upper gastrointestinal symptom severity index (PAGI-SYM) in patients with upper gastrointestinal disorders. Qual Life Res. 2004 Dec;13(10):1737-49. doi: 10.1007/s11136-004-9567-x.
Fass R, Chey WD, Zakko SF, Andhivarothai N, Palmer RN, Perez MC, Atkinson SN. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009 Jun 15;29(12):1261-72. doi: 10.1111/j.1365-2036.2009.04013.x. Epub 2009 Apr 8.
Ostovaneh MR, Saeidi B, Hajifathalian K, Farrokhi-Khajeh-Pasha Y, Fotouhi A, Mirbagheri SS, Emami H, Barzin G, Mirbagheri SA. Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: double-blind placebo-controlled trial. Neurogastroenterol Motil. 2014 May;26(5):670-8. doi: 10.1111/nmo.12313. Epub 2014 Feb 7.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
89-02-30-10638
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.